AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The selective estrogen-receptor modulator raloxifene doesn't appear to improve cognitive function in postmenopausal women, but it may delay cognitive decline, reported Dr. Kristine Yaffe of the University of California, San Francisco, and associates.
As part of a larger study on raloxifene's effects on osteoporosis, Dr. Yaffe and her associates assessed the cognitive performance of 7,478 postmenopausal women over the course of 3 years (N. Engl. J. Med. 344[16]:1207-13, 2001).
The women were randomly assigned to receive 60 mg of raloxifene, 120 mg of raloxifene, or a placebo daily. They ...